Replies to post #226417 on Biotech Values

[lgonber]

ACHN that is good news for us, long term investors, who swallow the nucleoside bluf but luckily bought the dip afterwards, hoping for a second chance with the platform D.

[DewDiligence]

ALXN/ACHN PR:

https://finance.yahoo.com/news/alexion-acquire-achillion-103000589.html

The premium to yesterday’s close (excluding the CVR) is 77%. The nominal deal value is $700M (excluding the CVR and the $230M of cash on ACHN’s latest balance sheet).